 nyse
figur may add due round
compani descript eli lilli compani
multi-national biopharmaceut compani focus
develop market innov medicin
area endocrinolog oncolog neurosci pain
autoimmun diseas compani also sell
strong quarter overshadow fda-
result report revenu billion
growth year-over-year exceed
estim billion street consensu
estim billion non-gaap ep well
ahead estim street consensu
guidanc manag rais end
revenu guidanc million rais end
oper ep guidanc page
much better anticip trulic also
outperform expect alimta exceed
estim small dollar term verzenio
provid view import beat anim
segment beat estim first time
neg highlight taltz meaning miss
estim yet anoth disappoint psoriasi
drug jardianc forteo also post lower-than-
forecast revenu cyramza revenu fell short
expect well gross margin non-gaap
contract basi point year-over-year
fall short estim
outlook estim outlook lilli remain
posit market still seem appreci
certain pipelin asset well margin expans
opportun furthermor remain confid lilli
diabet franchis face new competit
rais revenu oper ep
estim pleas see tabl left page
valuat rate use price-to-earnings dcf
valuat methodolog see page maintain
two year price target long-term buy
note import disclosur page
note analyst certif page
confer call note
confer call cover fairli wide rang topic opinion two meaning
topic focus baricitinib pain portfolio
could misread tea leav manag seem calmli confid
baricitinib applic remind investor fda advisori committe adcomm vote
approv mg dose due safeti concern support approv mg
dose rare occas fda act contrari adcomm recent histori suggest
unmet need high particularli rare and/or acut diseas consid pfizer
alreadi jak inhibitor baricitinib mechan action market rheumatoid arthriti
other jak inhibitor develop believ best investor take
conserv approach rule mg approv one interest comment
manag give investor hope christi shaw presid lilli
bio-medicin point vote specif focus indic
rheumatoid arthriti patient alreadi tri methotrex believ fda would
necessarili go adcomm approv mg dose patient
fail multipl therapi patient risk reward mg baricitinib could arguabl
becom favor manag note multipl time clinic trial real-world evid still
shown new safeti signal
pain portfolio seem come greater focu analyst commun view
clear posit analyst chatter lack product launch mere quarter two ago
convers pain portfolio focus galcanezumab cgrp antibodi
fda review migrain prevent cgrp field admittedli crowd think lilli
favor posit like bare beat lilli market time differ
enough truli establish first-mov advantag accord lilli manag concur
point lilli breadth portfolio small market advantag signific
access advantag come discuss payer lilli breadth differenti
come two potenti sourc possibl indic cluster headach someth
cgrp develop pursu lasmiditan remind investor lasmiditan
receptor agonist develop acut treatment migrain believ
lasmiditan well-posit commerci success mechan approach market
due superior safeti data lasmiditan also safeti advantag older therapi market
price like push patient tri older option move lasmiditan manag
also point addit data point efficaci galcanezumab competitor claim
also remind investor pain portfolio could add tanezumab road non-opioid
treatment chronic pain believ drug signific potenti yet doesnt seem
appreci market
revenu growth exceed estim street consensu volum growth
segment driven mostli new product volum growth
 europ best perform region term volum growth
addit tailwind foreign exchang rate currenc tailwind volum
growth off-set headwind biannual price cut lead japan growth
neurosci portfolio continu dwindl beat estim portfolio lose
remain exclus year
within endocrinolog humalog deliv strong beat favor price relat lower
medicaid util otherwis estim revenu humalog roughli flat year-over-
year although intern revenu post solid growth interest see medicaid
util truli plateau manag believ remind investor humalog also fresh
competit sanofi biosimilar market solid humulin growth domest
off-set buy pattern china trulic continu outpac estim rapidli grow
class market share gain deliv solid out-performance trulic key concern
market opinion consid strong new competit novo nordisk jardianc revenu
post strong growth fell short estim share new therapi start nt rx
essenti flat-lin despit view best-in-class manag note compani
absorb headwind formulari access problem larg pharmaci benefit manag
quarter forteo surpris downsid due declin domest manag blame
inventori stock also note formulari issu new competit
radiu health tymlo suspect last year domest growth rate repeat
immunolog portfolio continu expand small base left us disappoint much
taltz miss result inventori stock even exclud fact fell short price
concern crept indic therapeut class far sooner expect although
manag refut suggest analyst addit jnj tremfya present anoth
challeng howev remain confid taltz prospect especi lilli expand new
indic psoriat arthriti ankylos spondyl
within oncolog portfolio alimta exceed estim domest revenu grew
drug addit tailwind data merck keytruda pleas see
recent bristol-my squibb report discuss outsid european market alimta
sale stabl remind investor european market fractur drug
lost exclus countri other cyramza fell short estim japanes
revenu essenti flat verzenio post sequenti growth manag note
new-to-brand nbrx market share alreadi second quarter market
optim continu grow regard market share breast cancer take wait-and-
see approach regard potenti indic expans outsid breast cancer manag
note feedback verzenio quit posit includ perform poor prognosi patient
verzenio growth opportun result market expans whole class
believ poor prognosi patient popul key entri point outright market share theft
lartruvo continu perform well
ciali revenu exceed estim much like neurosci portfolio cardiovascular
portfolio critic lilli futur due gener market near horizon
anim final deliv solid quarter rel expect companion anim
ca segment carri day due new product livestock segment declin
 cattl market present problem competit market access manag
note poultri busi outperform industri outsid discontinu item
anim health unit manag post growth
gross margin decreas basi point fall short
estim decreas driven primarili foreign exchang rate lesser
oper expens line estim higher expect ms expens
equal off-set lower expect expens ms expens continu impact
conflict factor support new product save product nearli patent
 expens declin partial result restructur one-tim expens
pre-tax profit billion exceed estim billion primarili due
top line beat adjust non-gaap effect tax rate versu estim
non-gaap ep versu estim street consensu
estim
news item sinc last quarterli updat februari
lilli receiv fda approv verzenio treatment first-lin metastat breast cancer
hr remind investor verzenio alreadi approv
lilli announc success phase trial test cyramza hepatocellular
carcinoma detail data avail yet cyramza would enter increasingli
competit field hand cyramza fail reach statist signific overal
surviv os bladder cancer despit succeed progression-fre surviv
lilli present data baricitinib mirikizumab taltz atop dermat variou psoriat
diseas american academi dermatolog annual meet data gener strong
except baricitinib atop dermat rel competit view
lilli publish strong data regard trulic combin inhibitor
jardianc type diabet speak jardianc lilli partner boehring ingelheim
invest behind drug heart failur exercis capac trial collabor
univers oxford chronic kidney diseas
lilli announc multipl collabor advanc type diabet research includ one cell
therapi sigilon therapeut
increas revenu estim billion versu prior estim
billion also increas non-gaap ep estim increas
revenu estim billion billion increas oper ep
noteworthi chang
increas humalog trulic estim result strength quarter although
fundament outlook basic unchang increas alimta verzenio estim
function strong result increas optim potenti final lower
taltz olumi estim still gener posit taltz increas competit lead
us lower peak expect olumi hand releg intern
stori note assum mg dose approv therefor lower
long-term forecast significantli revenu estim chang modest
expens estim modest tweak align guidanc make materi
chang long-term gross margin oper expens assumpt except
lower tax rate
close yesterday trade next month non-gaap ep estim far
lowest forward price-to-earnings stock nearli four year furthermor low price-to-earnings base
rough neurosci drug lose exclus gener entri ciali loom
believ futur beyond much brighter investor therefor look low
multipl estim base expect compani growth profil risk
profil view low rel industri believ price-to-earnings set expans two
year price target deriv two methodolog discount free cash flow forward
price-to-earnings forward price-to-earnings portion deriv proprietari method assess
biopharmaceut industri basi risk growth risk measur product concentr
growth determin combin estim market assumpt
long-term growth peer result multipl appli ep
estim price target note use estim given weaker earn qualiti
although project earn qualiti increas next year discount free cash
flow assumpt includ wacc result higher interest rate howev
note could chang compani releas balanc sheet cash flow statement
quarter yet termin growth rate estim ad back net cash dcf
model result price target equally-weight two method assign share unchang
price target maintain long-term buy rate
 co larg well-establish biopharmaceut compani diversifi portfolio
robust pipelin feel compani balanc sheet cash flow solid base
consider assign share suitabl rate
competit innov biopharmaceut busi requir complex oper
mani uniqu uncertain aspect competitor new compani could produc new therapi
could displac lilli drug
regulatori biopharmaceut industri subject intens regulatori environ
throughout product life cycl regulatori action compani individu product
legal product lawsuit extrem common biopharmaceut sector unfavor
court decis could hamper abil market product subject compani earlier gener
price stock mention
includ estim risk-adjust revenu pipelin
compani report hilliard lyon estim
addit inform avail upon request
kurt kemper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
